Article
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
BMC cancer - 29 May 2013
Miyanaga Akihiko, Shimizu Kumi, Noro Rintaro, Seike Masahiro, Kitamura Kazuhiro, Kosaihira Seiji, Minegishi Yuji, Shukuya Takehito, Yoshimura Akinobu, Kawamoto Masashi, Tsuchiya Shinichi, Hagiwara Koichi, Soda Manabu, Takeuchi Kengo, Yamamoto Nobuyuki, Mano Hiroyuki, Ishikawa Yuichi, Gemma Akihiko
Abstract excerpt
BACKGROUND: The EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLCs). The EML4-ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS. CASE PRESENTATION: We report that a case of EML4-ALK-positive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.